CD4 and medullary thyroid gland carcinoma: Furthermore, we also evaluated the correlation between IDO2 and the CD4 + T expression of this relatively rare malignancy to outline IDO2 as both a potential new biomarker for better patient risk stratification and as a possible target for the immune therapy of MTC.